Security record · archived quarter
ITCI
Intra-Cellular Therapies, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
14Tracked holders
—Δ holders
9.81MShares held
$671.63MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2025 | 17 | +2 | 13.58M | $1.79B | +3 | −1 |
| Q4 2024 | 15 | +1 | 12.62M | $1.05B | +1 | — |
| Q3 2024 | 13 | -1 | 9.99M | $731.14M | +1 | −2 |
| Q2 2024 | 14 | — | 9.81M | $671.63M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 1.94M | — | $133.13M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.69M | — | $115.52M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.69M | — | $115.52M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.43M | — | $97.83M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.43M | — | $97.83M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.25M | — | $85.81M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.25M | — | $85.81M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.25M | — | $85.81M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.25M | — | $85.81M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.25M | — | $85.81M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 1.25M | — | $85.81M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 889.10K | — | $60.89M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 580.36K | — | $39.75M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 580.36K | — | $39.75M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 554.19K | — | $37.96M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | Adage Capital Partners ✦ | 501.17K | — | $34.33M | 0.1% | n/c | 1 | SEC ↗ |
| 17 | Marshall Wace ✦ | 499.01K | — | $34.18M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Marshall Wace ✦ | 499.01K | — | $34.18M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 222.40K | — | $15.23M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 133.67K | — | $9.16M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 133.67K | — | $9.16M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 105.43K | — | $7.22M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 105.43K | — | $7.22M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 105.43K | — | $7.22M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 5.29K | — | $362,038 | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Arrowstreet Capital ✦ | 3.91K | — | $268,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1 shares, $2,540 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API